Immunome, Inc. $IMNM Shares Acquired by NEOS Investment Management LLC
NEOS Investment Management LLC has increased its stake in Immunome, Inc. ($IMNM) by 40.5%, now owning 162,186 shares valued at approximately $1.90 million. Institutional investors collectively own 44.58% of the company, while insiders have also been actively buying, acquiring 68,518 shares worth roughly $1.45 million in the last 90 days. Analysts maintain a "Moderate Buy" rating with an average target price of $31.75, signalling positive sentiment despite a recent 2.9% dip in the stock.
Immunome CEO Touts Phase 3 Desmoid Win, Near-Term FDA NDA Plan and Early IM-1021 ADC Responses
Immunome CEO Clay Siegall highlighted the company's Phase 3 success with varegacestat in desmoid tumors, anticipating an FDA NDA submission in the coming months for a potential billion-dollar market. He also discussed promising early Phase 1 results for the IM-1021 ADC program, which targets ROR1 in lymphomas, and the company's broader strategy in targeted oncology focusing on cell-surface biologics and small molecules. Immunome plans to submit three more INDs this year and commence a radioligand therapy trial soon.
Trading Systems Reacting to (IMNM) Volatility
The article analyzes Immunome Inc. (IMNM) volatility, highlighting a weak near and mid-term sentiment but a positive long-term outlook. It presents institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with AI-generated signals for support and resistance levels. The analysis identifies an exceptional risk-reward setup targeting a 19.5% gain.
H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus
H.C. Wainwright has initiated analyst coverage on Immunome (NasdaqCM:IMNM), highlighting its oncology pipeline and strategic positioning. The new coverage brings increased scrutiny to the company's progress in cancer therapeutics, especially regarding pipeline development, funding, and upcoming clinical and partnering updates. Despite Immunome's significant stock returns over the past years, it faces challenges as an unprofitable company, emphasizing the importance of external funding and careful management of dilution risk for investors.
H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus
H.C. Wainwright has initiated analyst coverage on Immunome (NasdaqCM:IMNM), highlighting its oncology pipeline and strategic positioning. The coverage is expected to increase investor scrutiny on Immunome's execution of cancer drug programs, funding, and upcoming clinical and partnering milestones. Despite a strong past performance, the company is unprofitable, but analysts see it as potentially undervalued with significant revenue growth and stock price appreciation forecasts.
Immunome (NASDAQ:IMNM) Stock Rating Upgraded by HC Wainwright
HC Wainwright upgraded Immunome (NASDAQ:IMNM) to a "strong-buy" rating, with other firms also raising price targets, leading to a consensus "Moderate Buy" rating and a $31.75 price target. Insider activity includes a significant purchase by Philip Tsai, while Director Isaac Barchas sold a large block of shares. The company, a clinical-stage biotechnology firm, focuses on antibody-based therapeutics for oncology and infectious diseases.
H.C. Wainwright Coverage Puts Immunome Oncology Pipeline And Execution In Focus
H.C. Wainwright has initiated analyst coverage on Immunome (NasdaqCM:IMNM), drawing attention to its oncology pipeline and strategic positioning. The company's stock has seen significant returns over the past year and three years but is currently unprofitable, with analysts not expecting profitability in the next three years. This new coverage highlights the importance of Immunome's execution on drug programs, funding management given past dilution, and communication of clinical and partnering updates to investors.
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com
H.C. Wainwright initiated coverage on Immunome Inc. (NASDAQ:IMNM) with a Buy rating and a $40.00 price target, seeing a 71% upside from the current price. The firm highlighted Immunome's lead asset, varegacestat, for desmoid tumors, projecting over $1 billion in peak sales by 2034, and also noted its promising ADC franchise. Recent positive developments include a $400 million equity financing and reiterated Buy ratings from Guggenheim and Evercore ISI following strong Phase 3 trial results.
H.C. Wainwright initiates coverage on Immunome stock with Buy rating
H.C. Wainwright has initiated coverage on Immunome Inc. (NASDAQ:IMNM) with a Buy rating and a $40.00 price target, citing the company's strong oncology pipeline and lead asset, varegacestat. The firm believes varegacestat, a gamma-secretase inhibitor for desmoid tumors, could achieve over $1 billion in peak sales by 2034. Immunome recently secured $400 million in equity financing to advance its pipeline, including its ADC franchise and a FAP-targeted radioligand therapy, while receiving supportive analyst ratings from Guggenheim and Evercore ISI.
H.C. Wainwright initiates coverage on Immunome stock with Buy rating
H.C. Wainwright has initiated coverage on Immunome Inc. (NASDAQ:IMNM) with a Buy rating and a $40 price target, citing the company's strong oncology asset portfolio and the potential of its lead asset, varegacestat, for desmoid tumors. The firm projects varegacestat to achieve over $1 billion in peak sales by 2034 and highlights Immunome's ongoing development of next-generation antibody-drug conjugates (ADCs). This positive outlook comes as Immunome recently secured $400 million in equity financing to advance its pipeline and potential commercial launch.
Immunome (IMNM) Initiates Coverage with a Buy Rating by HC Wainw
HC Wainwright & Co. initiated coverage on Immunome (IMNM) with a Buy rating and a $40.00 price target, signaling a positive outlook for the company. This follows several other analysts reiterating Buy or Outperform ratings and raising price targets for Immunome in recent months. The biopharmaceutical company focuses on developing antibody therapeutics for oncology and infectious diseases, with its current pipelines including IM-1021.
HC Wainwright Initiates Immunome at Buy With $40 Price Target
HC Wainwright has initiated coverage on Immunome (IMNM) with a "Buy" rating and a price target of $40. This news comes as Immunome continues its work in developing targeted cancer therapies, including immunotherapies and radioligand therapies. The company recently reported positive topline results from its Phase 3 RINGSIDE trial for varegacestat in patients with desmoid tumors.
H.C. Wainwright initiates coverage on Immunome stock with Buy rating By Investing.com
H.C. Wainwright initiated coverage on Immunome Inc. (NASDAQ:IMNM) with a Buy rating and a $40.00 price target, representing a 71% upside. The firm highlighted Immunome's lead asset, varegacestat, for desmoid tumors, and its next-generation ADC franchise, expecting potential peak sales exceeding $1 billion by 2034 for varegacestat. Despite current unprofitability, Immunome's strong financial health and recent $400 million equity financing are viewed positively, with other analysts also raising price targets due to promising trial results.
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
H.C. Wainwright analyst Andres Y. Maldonado initiated a Buy rating for Immunome (IMNM) with a $40 price target, citing the company's strong oncology portfolio and ADC platform. Key factors include varegacestat's potential in desmoid tumors and the innovative ADC platform targeting chemoresistance. This builds on positive corporate insider sentiment and another recent upgrade by TipRanks - Google with a $30 price target.
Immunome (IMNM): Biotech minnow in the spotlight as volatility returns to cancer drug hunters
Immunome's stock has seen recent volatility as investors weigh its antibody discovery platform and oncology pipeline against valuation concerns. Despite recent swings, the stock has shown an overall upward trend over the past year, rewarding patient investors. Wall Street analysts largely hold a "Buy" or "Outperform" consensus, anticipating significant upside based on clinical and strategic milestones, although some advocate for a "Hold" due to early-stage assets and inherent development risks.
Principal Financial Group Inc. Buys 762,147 Shares of Immunome, Inc. $IMNM
Principal Financial Group Inc. significantly increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 222.3% in the third quarter, acquiring 762,147 shares to own a total of 1,104,938 shares valued at approximately $12.94 million. Institutional investors now own 44.58% of the company's stock, and analysts maintain a "Moderate Buy" consensus with an average target price of $31.00. The article also notes recent insider transactions, including a director's sale and an insider's purchase.
Candriam S.C.A. Buys 541,441 Shares of Immunome, Inc. $IMNM
Candriam S.C.A. significantly increased its stake in Immunome, Inc. (NASDAQ:IMNM) during the third quarter, purchasing an additional 541,441 shares to own a total of 859,527 shares, valued at approximately $10.07 million. This move reflects a growing positive sentiment among institutional investors and analysts, with several firms raising their price targets on Immunome. While insider activity was mixed, with one director selling shares and the CEO buying, the overall institutional ownership remains strong at 44.58%.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule
Immunome has reported inducement grants made under Nasdaq Listing Rule, according to a Reuters article republished by TradingView. The announcement refers to specific grants provided by Immunome management and falls under the "Refinitiv" news category.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced the grant of inducement awards consisting of non-statutory stock options to a new employee. These options, under the Company’s 2024 Inducement Plan, cover 30,000 shares of common stock at an exercise price of $26.14 per share and will vest over four years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. announced that its Compensation Committee granted inducement awards of non-statutory stock options to a new employee on February 2, 2026. The awards consist of options to purchase 30,000 shares of common stock with an exercise price of $26.14 per share, vesting over four years. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) to induce the employee's employment.
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Immunome, Inc. announced its management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. The company, focused on targeted cancer therapies, will provide a live audio webcast of the presentation. Immunome is advancing a pipeline that includes varegacestat, IM-1021, and IM-3050, as well as early-stage antibody-drug conjugates.
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Immunome, Inc. announced that its management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. The company, a clinical-stage targeted oncology firm, will provide a live audio webcast of the presentation from its investor relations website, with a replay available for approximately 30 days. Immunome is focused on developing first-in-class and best-in-class targeted cancer therapies.
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Immunome, Inc. announced that its management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. The company, a clinical-stage targeted oncology firm, will offer a live audio webcast of the presentation from its investor relations website, with a replay available for approximately 30 days. Immunome is developing a pipeline of targeted cancer therapies, including varegacestat, IM-1021, and IM-3050.
Immunome (IMNM) Receives a Buy from Wedbush
Wedbush maintained a Buy rating on Immunome (IMNM) with a price target of $31.00. This follows a previous Buy rating from TipRanks – Google’s Google Biotechnology on January 28, though TipRanks – OpenAI reiterated a Hold rating yesterday. Immunome reported a GAAP net loss of $57.46 million for the quarter ending September 30, and corporate insider sentiment is positive, with the CEO recently purchasing shares.
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Immunome, Inc. announced that its management will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026, at 9 a.m. ET. Interested parties can access a live audio webcast of the presentation via the Investor Relations section of the company’s website. Immunome is a clinical-stage targeted oncology company developing first-in-class and best-in-class targeted cancer therapies.
Immunome stock hits 52-week high at $26.74 By Investing.com
Immunome Inc.'s stock reached a 52-week high of $26.74, driven by a 153.29% increase over the past year and significant analyst confidence. Recent positive Phase 3 trial results for its desmoid tumor treatment and a $400 million public offering to fund commercial launch and pipeline development have contributed to this surge. Despite high volatility, analysts have raised price targets, indicating strong beliefs in the company's future prospects.
Immunome stock hits 52-week high at $26.74
Immunome Inc. (NASDAQ:IMNM) stock reached a 52-week high of $26.74, reflecting a significant 153.29% appreciation over the past year. This surge is attributed to growing investor confidence in the biotechnology sector, recent strategic developments, and positive analyst reactions to Phase 3 trial results and a public offering. The company is raising approximately $400 million through a public offering to support commercial launch and pipeline development.
Immunome, Inc. (NASDAQ:IMNM) Short Interest Down 12.6% in January
Immunome, Inc. (NASDAQ:IMNM) experienced a 12.6% decrease in short interest in January, totaling 15,314,650 shares, which represents about 18.1% of its shares short with a days-to-cover ratio of 6.2. Analyst sentiment for IMNM is largely positive, with a "Moderate Buy" consensus rating and an average price target of $31, while insider activity is mixed with some notable acquisitions and sales. The company's stock shows a 50-day simple moving average of $21.45 and a 200-day simple moving average of $15.69, with a market capitalization of $2.40 billion.
Nan Fung Trinity HK Ltd. Has $6.93 Million Position in Immunome, Inc. $IMNM
Nan Fung Trinity HK Ltd. increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 7.9% in the third quarter, bringing its total holdings to 592,103 shares valued at approximately $6.93 million. This represents 0.68% of Immunome. The company also saw significant insider trading activity, with CEO Clay B. Siegall purchasing shares and a director selling a larger proportion, while analysts generally hold a "Moderate Buy" consensus rating with an average price target of $31.00.
Institutional Investors Are Immunome, Inc.'s (NASDAQ:IMNM) Biggest Bettors and Were Rewarded After Last Week's US$382m Market Cap Gain
Institutional investors hold a significant 80% ownership in Immunome, Inc. (NASDAQ:IMNM), indicating their strong belief in the company. Following a US$382 million market cap gain last week, these investors were rewarded, contributing to a 160% one-year return. The article highlights that while institutional ownership is dominant, the top 9 shareholders hold 51% of the business, and insiders also have a meaningful stake, suggesting aligned interests.
Immunome stock reaches 52-week high at $25.32
Immunome Inc. (IMNM) stock has hit a new 52-week high of $25.32, marking a 143.58% increase over the past year. This surge is attributed to growing investor confidence, the company's strong financial stability, and recent positive developments including a $400 million equity financing and favorable Phase 3 trial results for its therapeutic asset, varegacestat. Analysts at Guggenheim and Evercore ISI have subsequently raised their price targets for the company.
(IMNM) and the Role of Price-Sensitive Allocations
This article provides an analysis of Immunome Inc. (NASDAQ: IMNM), highlighting strong sentiment across all horizons and an ongoing breakout. It details specific AI-generated trading strategies including position, momentum, and risk-hedging, along with multi-timeframe signal analysis for support and resistance levels. The report also notes an elevated downside risk due to a lack of additional long-term support signals.
Immunome stock reaches 52-week high at $25.32 By Investing.com
Immunome Inc. (IMNM) has reached a new 52-week high of $25.32, reflecting a 143.58% increase over the past year and significant investor confidence. The company recently announced a $400 million equity financing to extend its cash runway and develop pipeline assets, with analysts from Guggenheim and Evercore ISI raising price targets following positive Phase 3 trial results for varegacestat.
Immunome stock reaches 52-week high at $25.32
Immunome Inc. (IMNM) stock achieved a new 52-week high reaching $25.32, marking a 143.58% increase over the past year. This surge is attributed to growing investor confidence, significant financial moves including a $400 million equity financing extending its cash runway into 2028, and positive Phase 3 trial results for its drug varegacestat. Analysts have raised price targets, reflecting strong market sentiment and clinical advancements for the biotechnology company.
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM)
This article provides an overview of recent analyst ratings for three healthcare companies: Revolution Medicines (RVMD), Teladoc (TDOC), and Immunome (IMNM). Wedbush reiterated a Buy for Revolution Medicines, while Truist Financial maintained a Hold on Teladoc. LifeSci Capital reiterated a Buy rating for Immunome, highlighting their average price targets and potential upsides or downsides.
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Teladoc (TDOC) and Immunome (IMNM)
This article provides analyst ratings for three healthcare companies: Revolution Medicines (RVMD), Teladoc (TDOC), and Immunome (IMNM). Wedbush reiterated a Buy rating for RVMD, Truist Financial maintained a Hold for TDOC, and LifeSci Capital upheld a Buy rating for IMNM, with specified price targets and analyst success rates included.
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA Plan - What's Changed
Immunome Inc. (IMNM) experienced a 6.4% stock increase following positive Phase 3 trial results for its drug Varegacestat, which showed improved progression-free survival in desmoid tumors. The company plans to seek FDA approval in Q2 2026, positioning Varegacestat as a significant addition to its oncology pipeline. However, despite the clinical success, the company remains unprofitable with a history of dilution, and its future hinges on successful commercialization and execution post-approval.
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA Plan - What's Changed
Immunome (IMNM) has seen a 6.4% increase in stock price following strong Phase 3 data for its drug Varegacestat, which showed improved progression-free survival in the RINGSIDE trial. The company plans to seek FDA approval in Q2 2026, positioning Varegacestat as a key component of Immunome's oncology pipeline. While promising, the company still faces financial risks, including unprofitability and a history of shareholder dilution, though the trial results strengthen its investment narrative.
Immunome (IMNM) Is Up 6.4% After Strong Phase 3 Varegacestat Data and 2026 FDA Plan - What's Changed
Immunome (IMNM) reported positive Phase 3 RINGSIDE trial results for Varegacestat, showing improved progression-free survival and plans to seek FDA approval in Q2 2026. This data significantly strengthens Immunome's investment narrative, although the company still faces risks related to profitability, dilution, and share price volatility. The market is now evaluating how Varegacestat's success will translate into commercial approval and profitability for the company.
Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals
Immunome (IMNM) has seen significant share price momentum, with a 45.82% gain over the past three months and a 131.74% gain over the last year. While the company's Price-to-Book (P/B) ratio of 9.6x suggests it is overvalued compared to its industry and peers due to its loss-making status, a Discounted Cash Flow (DCF) model indicates the shares are trading significantly below their estimated fair value. This presents a conflict in valuation signals, prompting investors to consider whether market expectations are overstretched or if the long-term cash flow potential is being undervalued.
Immunome, Inc. $IMNM Holdings Boosted by Nisa Investment Advisors LLC
Nisa Investment Advisors LLC significantly increased its stake in Immunome, Inc. (NASDAQ:IMNM) by 3,513% in Q3, now owning 80,426 shares worth $942,000, contributing to the 44.58% institutional ownership. This boost comes alongside mixed insider activity, with a director selling a large number of shares while another insider made a notable purchase. Analysts maintain a "Moderate Buy" consensus despite the company missing quarterly EPS estimates and having a negative P/E ratio, indicating a blend of market optimism and fundamental challenges.
Wedbush Reiterates Outperform Rating for IMNM with $31 Price Target
Wedbush has reaffirmed its "Outperform" rating for Immunome (IMNM) and maintained a $31 price target, signaling confidence in the biopharmaceutical company's market performance. This reiteration comes alongside a series of upward adjustments in price targets from other analysts in recent months. Immunome is focused on developing first-in-class antibody therapeutics for oncology and infectious diseases using its human memory B cell platform.
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?
Immunome, Inc. (IMNM) is highlighted as a top booming stock, with its shares gaining 48% in the last three months, driven by positive Phase 3 RINGSIDE trial results for its desmoid tumor treatment, Varegacestat. The drug demonstrated an 84% reduction in the likelihood of death or disease progression, leading to multiple analysts raising their price targets and maintaining "Buy" or "Outperform" ratings. Immunome plans to seek FDA approval for Varegacestat in Q2 2026.
Immunome (NASDAQ:IMNM) Receives Outperform Rating from Wedbush
Wedbush reiterated an "Outperform" rating on Immunome (NASDAQ:IMNM), setting a $31 price target which suggests a 49% upside. Despite the positive rating, the company is currently unprofitable with a negative EPS of -$0.65 last quarter and a forecast of -$2.21 EPS for the current fiscal year. Insider activity includes a significant sale by Director Isaac Barchas and a purchase by CEO Clay Siegall, while institutional investors hold a substantial portion of the shares.
Wedbush Reiterates Outperform Rating for IMNM with $31 Price Target
Wedbush analyst David Nierengarten has reaffirmed an "Outperform" rating for Immunome (IMNM) with a price target of $31, indicating continued confidence in the company's performance. This reiteration follows several positive rating adjustments and price target increases from other analysts in recent months. Despite a positive Wall Street forecast with an average target price of $34.45, GuruFocus' estimated GF Value suggests a significant potential downside for the stock based on its intrinsic value calculation.
Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now?
Immunome, Inc. (IMNM) is gaining significant attention due to positive Phase 3 RINGSIDE trial results for its drug Varegacestat, which showed an 84% decreased likelihood of death or disease progression in desmoid tumor patients. Analysts have raised price targets significantly, with a consensus "Strong Buy" rating and a 61.40% upside potential. The company plans to seek FDA approval for Varegacestat in Q2 2026, positioning it for a potentially large share of the desmoid tumors market.
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation
Immunome (IMNM) is gaining attention after successful Phase 3 data for varegacestat and an upcoming J.P. Morgan presentation, with its share price rising significantly. While a Price-to-Book ratio of 8.8x suggests overvaluation compared to peers, a Discounted Cash Flow (DCF) model indicates the stock is deeply undervalued at $21.07, estimating a fair value of $131.20, prompting investors to consider whether market focus on current losses or future cash generation is more accurate.
Responsive Playbooks and the IMNM Inflection
This article provides an in-depth analysis of Immunome Inc. (NASDAQ: IMNM), highlighting positive near-term sentiment while noting a mid-term weak bias within a strong long-term context. It presents AI-generated institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for IMNM. The report suggests elevated downside risk due to a lack of additional long-term support signals.
Assessing Immunome (IMNM) Valuation After Phase 3 Success And Upcoming J.P. Morgan Conference Presentation
Immunome (IMNM) is gaining attention after positive Phase 3 data for varegacestat and an upcoming J.P. Morgan presentation. While its price-to-book ratio suggests overvaluation compared to peers, a Discounted Cash Flow (DCF) model indicates the stock might be significantly undervalued. Investors are prompted to consider whether the market is overly focused on current losses or if the DCF model is too optimistic about future cash generation.
Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms
Immunome (IMNM) shares rose 7.4% to $21.97, outperforming a broader biotech market rally, driven by optimism around its lead drug, varegacestat, for desmoid tumors. The company plans to file a New Drug Application with the FDA in Q2 2026 and expects to present at the J.P. Morgan Healthcare Conference on January 14. This movement follows positive Phase 3 trial results and a recent $400 million public offering, though future performance hinges on regulatory approvals and market reception.
